Reply to induction therapy and outcome in acute myeloid leukemia

Cancer

Volumn 117, Issue 10, 2011, Pages 2237-

  Rowe, Jacob M ^a   Kim, Haesook T ^b   Tallman, Martin S ^c  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; RETINOIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CANCER SURVIVAL; DRUG MEGADOSE; HUMAN; LETTER; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

EID: 79955485559     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25702     Document Type: Letter

References (2)

1. Rowe JM, Kim HT, Cassileth PA, et al. Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis: a report on 1980 patients registered to 6 studies conducted by the Eastern Cooperative Oncology Group. Cancer. 2010; 116: 5012 - 5021.
2. Kantarjian H, O'Brien S,. Questions regarding frontline therapy of acute myeloid leukemia. Cancer. 2010; 116: 4896 - 4901.